The Fifth Conference “ Nuclear Science and Its Application”, 14-17 October 2008
ESTIMATION
OF
DRUG-BINDING
CAPACITY
OF
HUMAN
SERUM PROTEINS WITH USE OF TRITIUM LABELED MEDICAL
PREPARATIONS
A.A.KIM1, JA.DADAKHANOV1. G.T.DJURAEVA1, B.V. SHUKUROV2, I.R.MAVLYANOV2
1 Institute o f Nuclear Physics, Uzbekistan Academy o f Sciences, Tashkent, Uzbekistan 2 Tashkent M edicine Academy, Tashkent, Uzbekistan.
The objective o f present study was investigation o f drug-binding capacity of human serum proteins at various hepatic pathologies. It is well known that at hepatic pathologies the synthesis o f serum albumin is reduced on background of increased intoxication o f organism by metabolites. These changes o f human serum proteins composition strongly reduce the ability of serum proteins to transport m edicinal preparations.
We investigated the drug-binding capacity of serum proteins o f patients with the help o f the tritium labeled pharmacological drugs o f furosemide and drotaverine (no-spa). These drugs were chosen due to their often use in standard therapy of hepatitis.
Series o f groups o f pediatric patients in the age o f 3 till 14 years with acute and chronic hepatitis A and B have been investigated. Control group includes die conditionally healthy children o f same age. The binding capacity o f serum proteins was determined by binding o f tritium labeled drotaverine and furosemide with serum proteins in vitro. The micromethod consists in incubation in vitro samples o f 20 microliter of serum with tritium-labeled drotaverine and with tritium labeled furosemide. After incubation serum proteins were fractionated by chromatography and tritium radioactivity bound with fraction o f serum proteins was measured.
It was found, that at the severe form o f virus hepatitis B the binding capacity of serum proteins was reduced actually o f all investigated patients in a stage o f peak of disease in comparison with control group. A t the moderate form o f acute virus hepatitis B the decrease o f binding capacity o f serum proteins was observed at 69 % o f patients.
We also investigated dynamics o f changes o f binding capacity o f serum proteins during standard therapy o f hepatitis A and B. We found, that during convalescence at application o f standard therapy the binding capacity o f serum proteins comes nearer to values of control group. Thus dynamics o f changes o f binding capacity o f serum proteins at patients with hepatitis B differed from dynamics at patients with hepatitis A. It was found, that children with an acute virus hepatitis B after basic treatment have increased level o f binding o f tritium labeled drotaverine by serum proteins, and at children with acute virus hepatitis A it does not occur.
Obtained results in the whole indicate the reducing o f binding capacity o f serum proteins at virus hepatitis that allows to determine the optimal strategy o f a pharmacological load on patient organism and thus to optimize the treatment of patients.
We suppose that used approach can be successfully applied for estimation o f the binding capacity o f serum proteins at other disfunctions o f transport system o f human blood proteins at various pathologies.
Section IV. Application O f Nuclear Technologies In Industry, Medicine And Agriculture
